IntuiTap Medical Appoints Ric Cote as Executive Chairman

HOUSTON--(BUSINESS WIRE)--IntuiTap Medical, a medical device company focused on improving the accuracy and efficiency of lumbar punctures and intrathecal drug delivery, announced the appointment of Ric Cote as Executive Chairman of the Board.

Mr. Cote brings decades of leadership experience in the medical device industry, with a track record spanning company building, commercialization, strategic growth, and successful exits. Most recently, he served as Chief Executive Officer and a member of the Board of Directors at Channel Medical Systems, where he led the company through FDA approval, global regulatory milestones, and multiple financing rounds. Across his career, he has held senior executive and board roles supporting medical technology companies from early clinical and regulatory stages through scale-up and value-creating outcomes.

“Ric’s depth of experience building and guiding medical device companies through critical inflection points makes him an ideal partner for IntuiTap at this stage of growth,” said Jessica Traver Ingram, Co-Founder and CEO of IntuiTap Medical. “As we focus on commercial expansion, strategic partnerships, and long-term value creation, Ric’s perspective and leadership will be invaluable.”

As Executive Chairman, Mr. Cote will work closely with IntuiTap’s leadership team and board to support corporate strategy, commercialization, and long-term value creation.

“I am excited to join IntuiTap Medical as Executive Chairman,” said Mr. Cote. “The caliber of the leadership team and the strength of the company’s differentiated technology stood out immediately and were central to my decision to join. I look forward to working closely with the team as they advance commercialization and build long-term value.”

IntuiTap Medical has received FDA clearance for its bedside imaging technology, which is designed to improve procedural accuracy while reducing reliance on blind techniques and fluoroscopy. The company is currently focused on expanding clinical adoption, refining its commercial strategy, and advancing partnerships across healthcare systems and industry.